Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces the amount of acid produced in the stomach.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Long-term management of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* H. pylori eradication (in combination with antibiotics)
## Adult Dosing
* **GERD (symptomatic relief):** 20 mg orally once daily. May increase to 40 mg once daily if needed.
* **Healing of erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Pathological hypersecretory conditions:** 40 mg orally twice daily. Doses may be increased to 80 mg twice daily based on clinical response.
* **H. pylori eradication:** 40 mg orally twice daily in combination with clarithromycin and amoxicillin or clarithromycin and metronidazole for 7-14 days.
## Pediatric Dosing
Dosing in pediatric patients is less established and should be guided by specific protocols and physician judgment.
* **GERD/Erosive esophagitis (ages 5-16 years):** 20 mg orally once daily for up to 4 weeks. Doses up to 40 mg daily have been used.
* **Safety and efficacy in children younger than 5 years for GERD are not established.**
## Dose Adjustments
No dose adjustment is generally needed for renal impairment.
For severe hepatic impairment, a maximum dose of 20 mg orally once daily is recommended.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
## Adverse Effects
Common: Diarrhea, headache, dizziness, abdominal pain, nausea, flatulence.
Long-term use: Increased risk of C. difficile infection, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, posaconazole, certain HIV protease inhibitors (e.g., atazanavir, nelfinavir), iron salts. Pantoprazole can decrease absorption.
* **Warfarin:** May increase INR and risk of bleeding. Monitor INR closely.
* **Methotrexate:** May increase methotrexate levels.
## Monitoring
* Monitor for signs and symptoms of C. difficile infection (severe or persistent diarrhea).
* Monitor serum magnesium levels, especially with prolonged use (>1 year) or concurrent use of diuretics or digoxin.
* Monitor for signs of bone fracture.
* For patients on warfarin, monitor INR.
## Clinical Pearls
* Administer 30-60 minutes before a meal.
* Do not crush or chew delayed-release tablets; swallow whole.
* For patients unable to swallow whole tablets, pantoprazole for injection can be reconstituted and administered orally or via NG tube, or the delayed-release tablets can be dispersed in 100 mL of applesauce or a similar soft food.
* Long-term PPI use is associated with potential risks; regularly reassess the need for continued therapy.
* Consider stepwise reduction in dose or intermittent therapy for patients nearing the end of their treatment course for erosive esophagitis.
***
**Disclaimer:** This information is intended for clinical use and does not replace the most current prescribing information. Always consult the official drug product labeling and relevant clinical guidelines for complete and up-to-date details before making any treatment decisions.
